Consequently, our data indicate that targeting molecular alterations of the PI3K/AKT/mTOR pathway in H3K27M glioma might represent a promising therapeutic approach worth validating in clinical trials that have already been initiated (27). Here, AKT1 is linked to central nervous system cancer.